Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-Blind, Placebo-Controlled, Randomized, Crossover Design Study With an Open-Label Active Control to Evaluate the Potential of Nestorone to Delay Cardiac Repolarization in Healthy Female Volunteers: A Thorough QT/QTc Study

Next Previous
Search
Trial Profile

A Double-Blind, Placebo-Controlled, Randomized, Crossover Design Study With an Open-Label Active Control to Evaluate the Potential of Nestorone to Delay Cardiac Repolarization in Healthy Female Volunteers: A Thorough QT/QTc Study

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 17 Aug 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Elcometrine (Primary) ; Moxifloxacin
  • Indications Menopausal syndrome
  • Focus Adverse reactions

Most Recent Events

  • 27 May 2016 Status changed from recruiting to completed.
  • 16 Apr 2015 Planned End Date changed from 1 Jan 2015 to 1 Sep 2015 as reported by ClinicalTrials.gov.
  • 16 Apr 2015 Planned primary completion date changed from 1 Nov 2014 to 1 Jun 2015 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top